Temporary Ovarian Suppression With Gonadotropin-Releasing Hormone Agonist During Chemotherapy for Fertility Preservation: Toward the End of the Debate?-Reference-Cited by-同舟云学术

Temporary Ovarian Suppression With Gonadotropin-Releasing Hormone Agonist During Chemotherapy for Fertility Preservation: Toward the End of the Debate?

Published:2015-10-13 Issue:11 Volume:20 Page:1233-1235
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Del Mastro Lucia¹,Lambertini Matteo²

Affiliation:

1. Department Of Medical Oncology, U.O. Sviluppo Terapie Innovative, IRCCS AOU San Martino-IST, Genova, Italy

2. Department of Medical Oncology, U.O. Oncologia Medica 2, IRCCS AOU San Martino-IST, Genova, Italy

Abstract

Temporary ovarian suppression with gonadotropin-releasing hormone agonist during chemotherapy might be a reliable strategy not only to preserve ovarian function but also to increase the likelihood of becoming pregnant after the end of cytotoxic therapy. The findings of Blumenfeld et al. are consistent with recent data suggesting the efficacy of this strategy in preserving fertility.

Funder

Associazione Italiana per la Ricerca sul Cancro

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.2015-0373

Reference16 articles.

1. Gonadotropin releasing hormone agonist cotreatment during chemotherapy may increase pregnancy rate in survivors;Blumenfeld;The Oncologist,2015

2. Fertility preservation in women with cancer;De Vos;Lancet,2014

3. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update;Loren;J Clin Oncol,2013